Lilly Strategy: Timely, Valued Medicines to Patients

Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline.

Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.

For more videos tune in to:

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!